Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells

Huang,Fang; Wu,Xiao-Nan; Chen,Jie; Wang,Wen-Xiang; Lu,Zu‑Fu

doi:10.3892/etm.2014.1662

Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells

Authors:
- Fang Huang
- Xiao-Nan Wu
- Jie Chen
- Wen-Xiang Wang
- Zu‑Fu Lu
View Affiliations

Affiliations: Department of Nutrition and Health Care, School of Public Health, Fujian Medical University, Fuzhou, Fujian 350004, P.R. China, School of AMME, The University of Sydney, Darlington, New South Wales 2050, Australia
Published online on: April 3, 2014 https://doi.org/10.3892/etm.2014.1662
Pages: 1611-1616

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although its mechanisms remain unidentified, resveratrol (trans‑3,4',5‑trihydroxystilbene; RES), which is an active, low molecular-weight compound, possesses a unique antitumor function and is capable of enhancing the cytotoxicity of doxorubicin (DOX) within solid tumor cells. RES is hypothesized to exert these effects by reversing the multidrug resistance (MDR) of the cancer cells in response to chemotherapeutic agents. The aim of the present study was to investigate the reversal effect of RES on MDR in human breast cancer DOX-resistant (MCF-7/DOX) cells and investigate the underlying mechanisms of RES. The results demonstrated that RES inhibited the proliferation of MCF-7/DOX and MCF-7 cells in a dose-dependent manner. Moreover, RES enhanced the cytotoxicity of DOX on MCF-7/DOX cells and the reversal index of RES treatment was demonstrated to be significantly higher when compared with that of the group without RES treatment. In addition, RES was observed to reverse the MDR of the MCF-7/DOX cells and elevate the concentration of DOX in the MCF-7/DOX cells. Furthermore, RES was identified to significantly downregulate the MDR-1 gene and P-glycoprotein expression levels. Reversing MDR, via the downregulation of MDR-1 expression, was concluded to be a mechanism of RES, which enables the unique antitumor function of this polypeptide. Therefore, the present study indicated that RES may be a novel MDR reversal agent for the treatment of breast cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global Cancer Statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM and Dickson RB: Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst. 84:1506–1512. 1992. View Article : Google Scholar : PubMed/NCBI
3	Robert J: Resistance to cytotoxic agents. Curr Opin Pharmacol. 1:353–357. 2001. View Article : Google Scholar
4	Avendaño C and Menéndez JC: Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem. 9:159–193. 2002.PubMed/NCBI
5	Ross DD: Novel mechanisms of drug resistance in leukemia. Leukemia. 14:467–473. 2000. View Article : Google Scholar : PubMed/NCBI
6	Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI
7	Tan B, Piwnica-Worms D and Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol. 12:450–458. 2000. View Article : Google Scholar : PubMed/NCBI
8	Mayer LD and Shabbits JA: The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance. Cancer Metastasis Rev. 20:87–93. 2001. View Article : Google Scholar : PubMed/NCBI
9	Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 34:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zhu HJ, Wang JS, Guo QL, Jiang Y and Liu GQ: Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6. Biol Pharm Bull. 28:1974–1978. 2005. View Article : Google Scholar : PubMed/NCBI
11	Zhou J, Liu M, Aneja R, Chandra R, Lage H and Joshi HC: Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res. 66:445–452. 2006. View Article : Google Scholar : PubMed/NCBI
12	Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:218–220. 1997. View Article : Google Scholar : PubMed/NCBI
13	Kundu JK and Surh YJ: Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 269:243–261. 2008. View Article : Google Scholar : PubMed/NCBI
14	Goswami SK and Das DK: Resveratrol and chemoprevention. Cancer Lett. 284:1–6. 2009. View Article : Google Scholar : PubMed/NCBI
15	Bishayee A: Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila). 2:409–418. 2009. View Article : Google Scholar : PubMed/NCBI
16	Huang F, Huang ZJ, Chen J and Wang JL: Studies of several polyphenolses on multidrug resistance to human breast carcinoma MCF-7/ADM Cell. J Pract Oncol. 24:121–123. 2009.(In Chinese).
17	Al-Abd AM, Mahmoud AM, El-Sherbiny GA, El-Moselhy MA, Nofal SM, El-Latif HA, et al: Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif. 44:591–601. 2011. View Article : Google Scholar : PubMed/NCBI
18	Hansen MB, Nielsen SE and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 119:203–210. 1989. View Article : Google Scholar : PubMed/NCBI
19	Chambers SK, Hait WN, Kacinski BM, Keyes SR and Handschumacher RE: Enhancement of anthracycline growth inhibition in parent and multidrug resistant Chinese hamster ovary cells by cyclosporin A and its analogues. Cancer Res. 49:6275–6279. 1989.PubMed/NCBI
20	Ganapathi R, Grabowski D, Rouse W and Riegler F: Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells. Cancer Res. 44:5056–5061. 1984.
21	Marques FZ, Markus MA and Morris BJ: Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol. 41:2125–2128. 2009. View Article : Google Scholar : PubMed/NCBI
22	Pozo-Guisado E, Merino JM, Mulero-Navarro S, Lorenzo-Benayas MJ, Centeno F, Alvarez-Barrientos A and Fernandez-Salguero PM: Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer. 115:74–84. 2005. View Article : Google Scholar : PubMed/NCBI
23	Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM and Castellón EA: Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl. 28:282–293. 2007. View Article : Google Scholar : PubMed/NCBI
24	Loo TW and Clarke DM: Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem. 277:44332–44338. 2002. View Article : Google Scholar : PubMed/NCBI